See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Baseball
Natural Disasters
Social Media
Education
Senate
Taxes
Soccer
Tariffs
Artificial Intelligence
Donald Trump
Stock Markets
Republican Party
Published • loading... • Updated

Very Low LDL-C Achieved With Evolocumab Not Associated With Long-Term Cognitive Impairment

Summary by Pharmacy Times
These results align with those from shorter-term analyses of low-density lipoprotein cholesterol (LDL-C) reductions with evolocumab and cognitive impairment risk.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Pharmacy TimesPharmacy Times

Very Low LDL-C Achieved With Evolocumab Not Associated With Long-Term Cognitive Impairment

These results align with those from shorter-term analyses of low-density lipoprotein cholesterol (LDL-C) reductions with evolocumab and cognitive impairment risk.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Pharmacy Times broke the news in on Friday, March 28, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal